严重急性呼吸综合征冠状病毒2型病毒样颗粒系统的优势与局限性
Strengths and limitations of SARS-CoV-2 virus-like particle systems.
作者信息
Sultana Rokaia, Stahelin Robert V
机构信息
Borch Department of Medicinal Chemistry and Molecular Pharmacology and The Purdue Institute of Inflammation, Immunology and Infectious Disease, Purdue University, 47907, West Lafayette, IN, USA.
Borch Department of Medicinal Chemistry and Molecular Pharmacology and The Purdue Institute of Inflammation, Immunology and Infectious Disease, Purdue University, 47907, West Lafayette, IN, USA.
出版信息
Virology. 2025 Jan;601:110285. doi: 10.1016/j.virol.2024.110285. Epub 2024 Nov 5.
Virus-like particles (VLPs) resemble the parent virus but lack the viral genome, providing a safe and efficient platform for the analysis of virus assembly and budding as well as the development of vaccines and drugs. During the COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the formation of SARS-CoV-2 VLPs was investigated as an alternative to authentic virions because the latter requires biosafety level 3 (BSL-3) facilities. This allowed researchers to model its assembly and budding processes, examine the role of mutations in variants of concern, and determine how the structural proteins interact with each other. Also, the absence of viral genome in VLPs circumvents worries of gains in infectivity via mutagenesis. This review summarizes the strengths and limitations of several SARS-CoV-2 VLP systems and details some of the strides that have been made in using these systems to study virus assembly and budding, viral entry, and antibody and vaccine development.
病毒样颗粒（VLPs）与亲本病毒相似，但缺乏病毒基因组，为病毒组装和出芽分析以及疫苗和药物开发提供了一个安全有效的平台。在由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的COVID-19大流行期间，由于真正的病毒体需要生物安全3级（BSL-3）设施，因此研究了SARS-CoV-2 VLPs的形成作为真实病毒体的替代方案。这使研究人员能够模拟其组装和出芽过程，研究关注变体中突变的作用，并确定结构蛋白之间如何相互作用。此外，VLPs中不存在病毒基因组避免了因诱变而导致传染性增加的担忧。本综述总结了几种SARS-CoV-2 VLP系统的优缺点，并详细介绍了在使用这些系统研究病毒组装和出芽、病毒进入以及抗体和疫苗开发方面取得的一些进展。
Zotero 插件